Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages.
Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, Johnson JE, Roth M, Beckermann KE, Rini BI, McKiernan J, Califano A, Drake CG. Obradovic A, et al. Among authors: ager c. Cell. 2021 May 27;184(11):2988-3005.e16. doi: 10.1016/j.cell.2021.04.038. Epub 2021 May 20. Cell. 2021. PMID: 34019793 Free PMC article.
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
Aggen DH, Ager CR, Obradovic AZ, Chowdhury N, Ghasemzadeh A, Mao W, Chaimowitz MG, Lopez-Bujanda ZA, Spina CS, Hawley JE, Dallos MC, Zhang C, Wang V, Li H, Guo XV, Drake CG. Aggen DH, et al. Among authors: ager cr. Clin Cancer Res. 2021 Jan 15;27(2):608-621. doi: 10.1158/1078-0432.CCR-20-1610. Epub 2020 Nov 4. Clin Cancer Res. 2021. PMID: 33148676 Free PMC article.
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.
Ager CR, Zhang M, Chaimowitz M, Bansal S, Obradovic A, Rogava M, Melms JC, McCann P, Spina C, Drake CG, Dallos MC, Izar B. Ager CR, et al. bioRxiv [Preprint]. 2023 Jan 2:2023.01.01.522340. doi: 10.1101/2023.01.01.522340. bioRxiv. 2023. Update in: J Immunother Cancer. 2023 Sep;11(9):e006782. doi: 10.1136/jitc-2023-006782 PMID: 36711647 Free PMC article. Updated. Preprint.
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators.
Obradovic A, Ager C, Turunen M, Nirschl T, Khosravi-Maharlooei M, Iuga A, Jackson CM, Yegnasubramanian S, Tomassoni L, Fernandez EC, McCann P, Rogava M, DeMarzo AM, Kochel CM, Allaf M, Bivalacqua T, Lim M, Realubit R, Karan C, Drake CG, Califano A. Obradovic A, et al. Among authors: ager c. Cancer Cell. 2023 May 8;41(5):933-949.e11. doi: 10.1016/j.ccell.2023.04.003. Epub 2023 Apr 27. Cancer Cell. 2023. PMID: 37116491 Free PMC article.
Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial.
Ager CR, Obradovic A, McCann P, Chaimowitz M, Wang ALE, Shaikh N, Shah P, Pan S, Laplaca CJ, Virk RK, Hill JC, Jugler C, DeFranco G, Bhattacharya N, Scher HI, DeCastro GJ, Anderson CB, McKiernan JM, Spina CS, Stein MN, Runcie K, Drake CG, Califano A, Dallos MC. Ager CR, et al. medRxiv [Preprint]. 2024 Sep 11:2024.09.09.24313308. doi: 10.1101/2024.09.09.24313308. medRxiv. 2024. PMID: 39314954 Free PMC article. Preprint.
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion.
Frangieh CJ, Melms JC, Thakore PI, Geiger-Schuller KR, Ho P, Luoma AM, Cleary B, Jerby-Arnon L, Malu S, Cuoco MS, Zhao M, Ager CR, Rogava M, Hovey L, Rotem A, Bernatchez C, Wucherpfennig KW, Johnson BE, Rozenblatt-Rosen O, Schadendorf D, Regev A, Izar B. Frangieh CJ, et al. Among authors: ager cr. Nat Genet. 2021 Mar;53(3):332-341. doi: 10.1038/s41588-021-00779-1. Epub 2021 Mar 1. Nat Genet. 2021. PMID: 33649592 Free PMC article.
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.
Ho P, Melms JC, Rogava M, Frangieh CJ, Poźniak J, Shah SB, Walsh Z, Kyrysyuk O, Amin AD, Caprio L, Fullerton BT, Soni RK, Ager CR, Biermann J, Wang Y, Khosravi-Maharlooei M, Zanetti G, Mu M, Fatima H, Moore EK, Vasan N, Bakhoum SF, Reiner SL, Bernatchez C, Sykes M, Mace EM, Wucherpfennig KW, Schadendorf D, Bechter O, Shah P, Schwartz GK, Marine JC, Izar B. Ho P, et al. Among authors: ager cr. Cancer Cell. 2023 Jul 10;41(7):1207-1221.e12. doi: 10.1016/j.ccell.2023.05.014. Epub 2023 Jun 15. Cancer Cell. 2023. PMID: 37327789 Free PMC article.
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, Ager C, Nicholas C, Jaiswal AR, Sun Y, Shah K, Balasubramanyam S, Li N, Wang G, Ning J, Zal A, Zal T, Curran MA. Jayaprakash P, et al. Among authors: ager c. J Clin Invest. 2018 Nov 1;128(11):5137-5149. doi: 10.1172/JCI96268. Epub 2018 Oct 15. J Clin Invest. 2018. PMID: 30188869 Free PMC article.
68 results